BeyondSpring Q3 2025 net loss $1.7M; Plinabulin DCR 85% in NSCLC post-PD-1/L1

BeyondSpring Inc.

2025-Q3 EPS reported -$0.03

Net loss from continuing ops $1.7M vs $2.2M YoY; cash $12.5M up from $2.9M Dec 2024.
Plinabulin + docetaxel + Keytruda in NSCLC: DCR 85%, median PFS 7.0 mo, 12-mo OS 79%.
SEED (38% owned) closed $30M Series A-3, FDA/NMPA IND clearance for RBM39 degrader.
R&D $1.0M, G&A $0.8M; headcount reductions drove lower admin expenses.
Discontinued ops (SEED sale accounting) net loss $3.2M in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.